Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
14 avr. 2020 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
06 avr. 2020 16h30 HE
|
Crinetics Pharmaceuticals, Inc.
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral...
RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
11 mars 2020 19h15 HE
|
Curium
Houston, TX and St. Louis, MO, March 11, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced the U.S. Food and Drug Administration (FDA) has granted copper Cu 64...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
09 mars 2020 16h10 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
08 janv. 2020 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
26 nov. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 16h04 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
25 sept. 2019 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
03 juin 2019 16h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
03 juin 2019 09h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...